Dalrada Appoints Harvey Hershkowitz as Chairman and CEO of Genefic

Health care veteran with nearly four decades in the medical, technology, and pharmacy industries named leader of new health division

Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada”), a problem-solving innovator that takes on complex, multi-disciplinary challenges in health care, clean energy, precision manufacturing, and technology, today announced the appointment of Harvey Hershkowitz as Chairman and Chief Executive Officer of Genefic (formerly Dalrada Health).

Mr. Hershkowitz has served as a board member of Dalrada Financial Corporation since July 2020, where his extensive track record in business and the health care industry has furthered Dalrada’s global vision and business expansion strategy.

Genefic will focus on improving health outcomes for people around the world through reimagined patient care, and Brian Bonar, Dalrada’s Founder and Chief Executive Officer, affirms that Hershkowitz is the ideal candidate for the position.

“As Genefic focuses on meeting the fast-paced requirements of quality health care through disruptive technologies, products, and services, we are extremely pleased that Mr. Hershkowitz has accepted the position as Genefic’s Chairman and CEO,” said Bonar. “Harvey has a deep understanding of the industry – and a clear, strategic vision to continue to drive growth and innovation.”

Mr. Hershkowitz brings more than 35 years of health care experience to Genefic, including leading top Fortune 10 companies. He has served as the President and a member of the Board of Directors for a number of health care companies and hospitals, boasting a notable track record of spring-boarding start-ups, securing funding for a variety of organizations, raising capital for 501C3 organizations, and positioning corporations in the global market.

Additionally, he has successfully spearheaded efforts to grow companies specializing in bioscience, pharmacy, and health care construction, and has facilitated the expansion of acute care hospitals, skilled nursing facilities, and major physician groups.

“I’m excited to help Genefic meet the fast-paced requirements of quality health care by driving disruptive technologies and developing advanced products and services,” said Hershkowitz.

Genefic looks forward to continually expanding its portfolio of companies and global footprint with the diligent and enthusiastic leadership of Mr. Hershkowitz.

For additional information on Dalrada and its subsidiaries, please visit www.dalrada.com. To learn more about Genefic, please visit www.genefic.com.

About Dalrada Financial Corporation

Dalrada Financial Corporation (OTCQB: DFCO) is a forward-facing organization that continually produces disruptive products and services that accelerate positive change for current and future generations.

Since 1982, Dalrada has redefined possibilities while boldly addressing global challenges with transformative innovations that drive targeted advances in emerging markets for a new era of human behavior and interaction, ensuring a bright future for the world around us.

Dalrada Financial Corporation is committed to positively impacting people, businesses, and the planet through sustainable solutions. For more information, please visit www.dalrada.com, and follow us on Twitter, Facebook, and LinkedIn.

About Genefic

With a dedicated commitment to health and wellness and improved patient care, Genefic delivers with bold ingenuity. Genefic creates key products and services and builds comprehensive solutions that provide better outcomes through reimagined health care systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, Genefic creates health innovations that make positive impacts around the world. To learn more, visit www.genefic.com.

Disclaimer

Statements in this press release are not historical facts. The statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations regarding these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the US Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005178/en/